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Abstract
The neuroendocrine (NE) cell is a minor cell population in normal human prostate glands. The number of NE cells is
increased in advanced hormone-refractory prostate carcinomas (PCA). The mechanism of increased NE cell population in
these advanced tumors is poorly understood. We examined molecular mechanisms which may be involved in the regulation
of the transdifferentiation process of human PCA cells leading to a NE phenotype. We compared PCA cell lines LNCaP and
PC-3 in the following medium conditions: steroid-reduced (SR), interleukin-6 (IL-6)-supplemented, or dibutyrate cAMP (db-
cAMP)-supplemented. We found that androgen-responsive C-33 LNCaP cells responded to all treatments, having a
neuronal-like morphology. In contrast, C-81 LNCaP cells, having a decreased androgen responsiveness, had a less
pronounced effect although followed a similar trend. Androgen-unresponsive PC-3 cells showed little change in their
morphology. Grown in the SR condition, the level of neuron-specific enolase (NSE), a marker of neuronal cells, was
upregulated in C-33 LNCaP cells, while to a lesser degree in the presence of IL-6. In the presence of db-cAMP, the NSE level
in C-33 cells was decreased, lower than that in control cells. An opposite effect was observed for C-81 LNCaP cells.
Nevertheless, the NSE level was only elevated in db-cAMP-treated PC-3 cells, but no change was found in PC-3 cells grown
in the SR- or IL-6-supplemented medium. Thus, a similar gross phenotypic change may correlate with differential molecular
expressions. We also analyzed the expression of protein tyrosine phosphatase K (RPTPK) since it plays a critical role in
normal neuronal differentiation and signaling. Our results showed that the expression of RPTPK correlates with the NE
phenotypic change of LNCaP cells in the SR condition. In summary, our data clearly show that the molecular process by
which cultured human prostate cancer cells undergo a transdifferentiation process to a NE cell-like phenotype is
accompanied by differential expressions of different markers, and a gross NE cell-like phenotype can occur by exposing PCA
cells to different pharmacological agents. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Prostate cancer is the most common malignancy in
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men, and the second leading cause of cancer-related
mortality in US males [49]. Although androgen abla-
tion is the most e¡ective therapy for patients with
advanced prostate cancer, progression of cancer cells
to androgen independence evidently occurs and re-
mains the main obstacle to improve the survival and
quality of life [21]. The tumor progression to andro-
gen-refractory stage is a complex process that may be
involving both clonal selection and adaptive mecha-
nisms in heterogeneous tumors composed of cells
that respond di¡erently to androgen ablation. The
present research is focused on understanding the mo-
lecular mechanisms that allow human prostate can-
cer cells to acquire androgen independence.
The cells in human prostate gland include basal
epithelial, secretory epithelial, and neuroendocrine
(NE) cells, in addition to stromal cells [7,23]. The
NE or endocrine^paracrine cells, although only rep-
resenting a minor cell population in normal prostate
glands, are known to produce and secrete some po-
tent neuro-hormones, including bombesin/gastrin,
calcitonin, and parathyroid hormone-related peptide,
that likely regulate the activity and homeostasis of
the adjacent basal and/or secretory epithelial cells
[31]. NE cells may represent one potential pathway
of di¡erentiation of prostatic stem cells. Recently,
results of several clinical studies suggested that NE
cells may also have a role in the progression of pros-
tate cancer cells to the hormone-independent state
[22,24,25]. Histological studies reveal that NE cells
are signi¢cantly more abundant in cancerous tissues
than in non-cancerous tissues [32]. In fact, the overall
abundance of NE cells is increased in proportion to
the progression of prostate cancer from the early
stage to the advanced, hormone-resistant state [61].
Results from analyses on sera from hormone-depen-
dent and clinically advanced, hormone-refractory
prostate cancer patients show an increased level of
chromogranin A [1,37] and neuron-speci¢c enolase
(NSE) [58], markers for NE cells, in advanced stage
patients. These observations have led to the hypoth-
esis that NE cells function to provide paracrine stim-
ulatory factors in an androgen-deprived condition,
leading to an accelerated growth and progression of
surrounding prostate cancer cells toward an andro-
gen-independent state. This hypothesis is supported
by the observation of an increased proliferation in-
dex of tumor cells in the close proximity to the NE
cell foci [9]. Thus, NE cells can apparently modulate
the proliferation of adjacent epithelial cells including
cancerous and non-cancerous cells.
Although the origin of the NE cell population in
prostate cancer tissues remains uncertain, a number
of recent studies has shown that prostate cancer cells
themselves have the ability to ‘transdi¡erentiate’ (or
convert) into cells with a NE-like phenotype in cul-
ture. This phenomenon can occur when cultured
prostate cancer cells are exposed to pharmacological
agents that increase the intracellular level of cyclic
AMP (cAMP) [4,16], in the presence of interleukin-
6 (IL-6) [47,51], or in a steroid-reduced medium
[10,55]. These treatments induce a morphological
change in cell phenotype, resembling cultured neuro-
nal cells with narrow cell bodies and elongated pro-
cesses. However, no systematic study has been per-
formed to analyze the susceptibility of each cell line
to di¡erent treatments that relate to clinical phenom-
ena. The molecular mechanism of transdi¡erentia-
tion also remains to be further delineated.
Protein tyrosine phosphorylation plays a critical
role in regulating various cellular events, including
cell di¡erentiation and proliferation. Protein tyrosine
kinases (PTKs) and protein tyrosine phosphatases
(PTPs) function dynamically to maintain cellular ho-
meostasis. Unbalanced tyrosine phosphorylation can
alter signaling for cell growth and di¡erentiation,
leading to neoplastic diseases or cell growth arrest.
Protein tyrosine phosphatase K (RPTPK), also
known as leukocyte common antigen-related phos-
phatase (LRP), is a transmembrane member of the
PTP family [39,40,54]. It has been demonstrated that
RPTPK can be involved in GRB2-mediated signaling
[19,57], and participate in activation of mitogen-acti-
vated protein kinases (MAPKs) and c-Jun transcrip-
tion [66]. Additionally, RPTPK can regulate the spe-
ci¢c activity of Src kinase by dephosphorylating its
carboxyl-terminal tyrosine [20,67]. Interestingly,
RPTPK has also been determined to play a critical
role in normal neuronal di¡erentiation [60,62]. Thus,
RPTPK is involved in multisignaling pathways. We
have reported that RPTPK mRNA is expressed in
normal and cancerous prostate cells [64]. However,
its functional role in those cells remains to be clari-
¢ed.
It has been established that modi¢cation of nucle-
osome structure is an important regulatory mecha-
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nism of gene expression. For example, butyrate is a
non-competitive inhibitor of histone deacetylase, and
thus provokes a hyperacetylation level of core his-
tones [44]. The hyperacetylation of histones by buty-
rate induces a more open state of chromatin, which
leads to the activation of expression of numerous
genes and cellular di¡erentiation [12], similar to
that by trichostatin A (TSA), a potent speci¢c inhib-
itor of histone deacetylase [63]. Butyrate treatment
can also increase the phosphorylation of MAPK,
i.e., ERK1/2 [27], and induce di¡erentiation in
many cell types [15,29,53]. Interestingly, some tran-
scriptional e¡ects by butyrate can be abolished by
inhibitors of protein phosphatases [17]. Thus, the
molecular mechanism of butyrate in cellular di¡er-
entiation involving phosphorylation signaling re-
mains to be delineated.
In an e¡ort to understand how NE cells progres-
sively emerge in prostate malignancies and their re-
lationship to hormone-refractory prostate carcino-
mas, we studied the pharmacological e¡ect on
transdi¡erentiation of two human prostate cancer
cell lines, LNCaP and PC-3. Although LNCaP pa-
rental cells, i.e. C-33 LNCaP cells, have been studied
with regard to their growth patterns in response to
various culture conditions, less is known about trans-
di¡erentiation of PC-3 cells nor is their transdi¡er-
entiation related to prostate cancer progression. We
also examined the transdi¡erentiation process of C-
81 LNCaP cells, a subline of LNCaP cells which lack
androgen responsiveness of growth stimulation, de-
spite the expression of a functional AR. We investi-
gated the biochemical parameters of transdi¡erentia-
tion, and examined the e¡ect of butyrate on
transdi¡erentiation of LNCaP cells. Our results sug-
gest that di¡erent transdi¡erentiation processes are
involved in the accumulation of NE cells in advanced
hormone-refractory human prostate cancers.
2. Materials and methods
2.1. Materials
Fetal bovine serum (FBS), cell culture medium
RPMI 1640, gentamicin, horseradish peroxidase-con-
jugated anti-mouse and anti-rabbit immunoglobulins
(IgGs) were purchased from Life Technologies
(Grand Island, NY). Charcoal/Dextran-treated, cer-
ti¢ed FBS with testosterone concentration below
3 ng/dl was from HyClone (Logan, UT). Protein
molecular weight standard markers, acrylamide,
and the protein assay kit were obtained from Bio-
Rad (Hercules, CA). Sodium butyrate, trichostatin
A, dibutyrate cAMP (db-cAMP), and L-actin-speci¢c
antibody were from Sigma (St. Louis, MO). IL-6 and
NSE-speci¢c antibodies were purchased from Up-
state Biotechnology (Lake Placid, NY). RPTPK-spe-
ci¢c antibody was obtained from Transduction
Laboratories (San Diego, CA). Gastrin (GS), chro-
mogranin A (ChA), and neurotensine (NT)-speci¢c
antibody and ABC Staining System were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
All other reagents were obtained as described in pre-
vious publications [30,42].
2.2. Methods
2.2.1. Cell culture
Commercially available human prostate carcinoma
cell lines, LNCaP and PC-3, were originally obtained
from the American Type Culture Collection, and
routinely maintained in phenol red (PR)-containing
RPMI 1640 medium supplemented with 5% FBS, 1%
glutamine, and 0.5% gentamicin, as described in pre-
vious publications [30,42]. LNCaP cells are andro-
gen-responsive and express PSA, while PC-3 cells
are androgen-insensitive and lack the expression of
PSA [38,42]. For experiments, LNCaP cells that had
passage numbers less than 33 were designated as C-
33, passage numbers between 80 and 120 as C-81, as
described in our previous publication [42]. Despite
the expression of functional AR in C-81 cells, the
degree of androgen-stimulating cell growth is de-
creased. Furthermore, the growth rate of C-81 cells
is more rapidly than that of C-33 cells with a dou-
bling time half that of C-33 cells [42]. For experi-
ments, cells were routinely seeded in PR-containing
RPMI 1640 medium supplemented with 5% FBS for
2 days prior to any treatment. The total cell number
was counted using a Coulter Counter Z1 model
[42,64].
2.2.2. E¡ect of steroid-depleted condition on prostate
cancer cells
For these experiments, LNCaP and PC-3 cells
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were plated in the regular medium at a cell density of
0.5U106 cells per T-25 £ask for PC-3 and C-81
LNCaP cells, and 1U106 cells per T-25 £ask for C-
33 LNCaP cells, and allowed to attach for 48 h. Cells
were then fed with a steroid-reduced (SR) medium,
i.e., PR-free RPMI 1640 medium containing heat-in-
activated 5% charcoal-stripped fetal bovine serum
(CS-FBS) and gentamicin, for 5 days as described
previously [64].
2.2.3. IL-6 and db-cAMP-induced neuroendocrine
di¡erentiation
Cell were seeded in a density of 0.5U106 cells per
T-25 £ask for PC-3 and C-81 LNCaP cells, and
1U106 cells per T-25 £ask for C-33 LNCaP cells in
RPMI 1640 medium containing 5% FBS for 2 days,
then 24 h in a SR medium, and followed by treat-
ment with 50 ng/ml IL-6 or 1 mM db-cAMP for
3 days as described previously [4,51].
2.2.4. Sodium butyrate e¡ect
A cell density of 1U106 cells per T-25 £ask for C-
33 LNCaP cells and 0.5U106 cells per T-25 £ask for
C-81 cells were plated in RPMI 1640 medium sup-
plemented with 5% FBS for 2 days. Cells were then
fed with a SR medium with or without sodium bu-
tyrate as described previously [64]. After 72 h, cells
were harvested for Western blot analyses.
2.2.5. Trichostatin A e¡ect
A cell density of 1U106 cells per T-75 £ask for C-
33 LNCaP cells was plated and maintained in RPMI
1640 medium supplemented with 5% FBS for 2 days.
Cells were then fed with a SR medium with or with-
out TSA. After 48 h, cells were harvested for West-
ern blot analysis.
2.2.6. Immunocytochemical analysis
For immunocytochemical analysis, C-33 LNCaP
cells were plated at 2U104 cells per well in four-
well glass slides (Nalge Nunc). Immunostaining was
performed after treatments with a modi¢ed avidin^
biotin complex technique [35]. Cells were washed
brie£y with PBS, ¢xed in 310‡C methanol for
5 min and air-dried. The nonspeci¢c immunoglobulin
binding was blocked by incubation with 1.5% normal
donkey serum (Santa Cruz Biotechnology) for GS,
NT, ChA antibodies or goat serum (Santa Cruz Bio-
technology) for NSE antibody for 1 h. The primary
antibodies were applied to cells and incubated for 30
min at room temperature. The slides were then incu-
bated with biotinylated IgG secondary antibody
(goat anti-mouse or donkey anti-goat depending on
the primary antibody host; Santa Cruz Biotechnol-
ogy) in PBS with 1.5% normal blocking serum at
room temperature for 30 min. Avidin^biotin com-
plexes were made according to the manufacturer’s
instructions, applied to the section, and incubated
at room temperature for 30 min. Immunopositivity
was visualized with the chromogen diaminobenzidine
(0.025%) in substrate bu¡er and 0.1% hydrogen per-
oxide. Immunostaining with the negative controls
(no primary antibody) was proceeded as described
for the primary antibody.
2.2.7. Western blotting of cellular protein and medium
Cells were harvested and lysed as described previ-
ously [46]. Brie£y, cells were scraped, pelleted and
rinsed with ice-cold HEPES-bu¡ered saline, pH 7.0,
then lysed in an ice-cold cell lysis bu¡er containing a
battery of protease and phosphatase inhibitors. The
cellular lysates were spun, the supernatants were re-
covered and the protein concentration was deter-
mined using the Bio-Rad protein assay kit. The me-
dium was harvested and spun at 4‡C for 10 min to
remove any cell debris before usage. For immuno-
blotting, an aliquot of total lysate protein (30 Wg) or
15 Wl of culture medium in a 2USDS^PAGE sample
bu¡er (1:1, v/v) was electrophoresed and transferred
to nitrocellulose ¢lters. Filters were incubated with
appropriate primary antibody in Tris-bu¡ered saline,
pH 7.5, containing 0.1% Tween 20 (TBST) and 5%
skim milk for 3 h, subsequently with secondary anti-
body in TBST bu¡er for 1 h. The protein bands
were visualized by an ECL detection system. For
reprobing, ¢lters were agitated with the stripping
bu¡er for 30 min at 50‡C [42,45]. After two washes
with TBST bu¡er, the ¢lters were reacted with spe-
ci¢c antibodies and the signal was detected by an
ECL method.
2.3. Data analysis
The intensities of hybridization bands were semi-
quanti¢ed by densitometric analyses of autoradio-
grams with di¡erent exposure time periods utilizing
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a Molecular Dynamics Computing Densitometer and
its software program.
3. Results
3.1. E¡ect of steroid-depleted medium, IL-6 and
db-cAMP on transdi¡erentiation of prostate
cancer cells
Since several pharmacological reagents have been
reported individually to induce transdi¡erentiation of
LNCaP or PC-3 human prostate cancer cells to a
NE-like phenotype, we examined if the same reagent
can have a similar e¡ect on these two prostate cancer
cells. C-81 LNCaP cells which exhibit androgen-un-
responsive cell growth despite the expression of func-
tional AR were also included for analysis. Due to the
androgenic activity of PR [41], all cells were main-
tained in a SR condition, i.e., PR-free, steroid-re-
duced medium, in the presence or absence of IL-6,
or db-cAMP. Control cells were maintained in the
routine growth condition, i.e. PR-positive medium
containing 5% FBS.
In the SR condition alone or with the addition of
db-cAMP or IL-6, PC-3 cells showed little change in
their morphology in comparison with control cells
grown in the PR-positive medium containing 5%
FBS (data not shown and [4]). C-33 LNCaP control
cells had an epithelial morphology (Fig. 1A), and
tended to grow in clusters with a somewhat acinar
appearance (data not shown). In contrast, in the SR
Fig. 1. Morphological changes of C-33 LNCaP cells induced by di¡erent pharmacological reagents. (A) Control LNCaP cells main-
tained in a PR-positive medium supplemented with 5% FBS; (B) LNCaP cells maintained in a PR-negative medium supplemented
with 5% SR-FBS; (C) LNCaP cells maintained in a PR-negative medium supplemented with 5% SR-FBS and 50 ng/ml IL-6; (D)
LNCaP cells maintained in a PR-negative medium supplemented with 5% SR-FBS and 1 mM db-cAMP. The photo of the morpho-
logical alternation was made at day 3 (A,C,D) and day 5 (B) of treatment (100U magni¢cation). Similar results were observed for C
and D with a 5 day treatment (data not shown).
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condition, C-33 LNCaP cells had a neuronal appear-
ance characterized by multipolar cells with small cell
bodies and long, irregular processes (Fig. 1B). Sim-
ilar morphologic e¡ects were seen for these cells
grown in the IL-6-containing medium although less
pronounced (Fig. 1C), while db-cAMP had a more
potent e¡ect on cellular morphology (Fig. 1D). In
comparison, C-81 LNCaP cells followed a similar
trend to C-33 LNCaP cells in the phenotype alterna-
tion although the e¡ect was less pronounced (data
not shown).
To determine whether acquisition of the NE-like
phenotype of C-33 LNCaP cells a¡ects the expres-
sion of distinct NE cell markers, immunocytochem-
ical stainings with antibodies against NSE, ChA, GS
and NT were performed. As shown in Fig. 2, LNCaP
cells expressed elevated levels of ChA and NT in SR
conditions or in the presence of IL-6 although the
Fig. 2. Immunostaining of neuroendocrine cell markers in LNCaP cells upon di¡erent treatments. Cell were seeded at 2U104 cells per
chamber on four-well glass slides in RPMI medium containing 5% FBS and treated as described in Section 2. Immunostaining was
performed using NSE, ChA, Gs, and NT primary antibodies. Photographs were taken at 200U magni¢cation.
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degree of elevation is low. These data showed that
LNCaP cells exhibit the ability to express ChA and
NT prior to induced transdi¡erentiation by exoge-
nous stimuli. In contrast, the immunoreactivity
with NSE and GS antibodies was found to be highly
increased in cells maintained in the SR condition and
in the presence of IL-6. Interestingly, while db-cAMP
had a potent e¡ect on cellular morphology (Fig. 1D),
it did not signi¢cantly a¡ect the levels of NSE, ChA,
GS, and NT. Nevertheless, the immunostaining
clearly showed increasing NE characteristics of C-
33 LNCaP cells in SR conditions including manifes-
tation of the cytoplasmic NE granules in ChA stain-
ing and the cytosolic staining of NSE. Thus, di¡erent
growth conditions including pharmacological re-
agents can induce NE-like phenotypic changes in
prostate cancer cells, while they may have di¡erential
e¡ects on the expression of biomarkers. Based on
these data, we used NSE as the major marker in
our further studies to monitor the transdi¡erentia-
tion process of LNCaP cells into NE-like cells.
Western blot analyses were performed to semi-
quantify the expression of NSE in cells grown in
di¡erent conditions. As shown in Fig. 3 in C-33
LNCaP cells grown in the SR condition, the NSE
level was elevated by approx. 3-fold, while to a lesser
degree with an addition of IL-6, as observed in Fig.
2. Unexpectedly, in the presence of db-cAMP, the
expression of NSE was decreased, even lower than
that in control cells grown in the regular growth
condition. An opposite e¡ect was observed in C-81
LNCaP cells in which the NSE level was decreased in
the SR condition, while elevated in db-cAMP-supple-
mented condition (Fig. 3). The level of NSE was not
signi¢cantly altered by adding IL-6 to those cells.
Interestingly, as shown in Fig. 3, PC-3 control cells
expressed a high basal level of NSE in comparison
with LNCaP cells. The NSE level was only elevated
in the db-cAMP-treated cells, but did not change in
the SR medium or IL-6-supplemented medium.
Thus, despite a similar e¡ect on the morphology of
C-33 and C-81 LNCaP cells by the steroid-reduced
condition and the db-cAMP supplement, these
growth conditions have an opposite e¡ect on the
NSE expression. Thus, di¡erential molecular expres-
sions can correlate with a similar gross phenotypic
change.
PC-3 cells are poorly di¡erentiated prostate cancer
cells, and do not express any known biomarkers in-
cluding PSA. Similar to the observations by Bang et
al. [4], we found that PC-3 cells only exhibited a
minor change in their phenotype and a marginal el-
evation of NSE level upon db-cAMP treatment. We
therefore focused our e¡orts on characterizing bio-
markers during transdi¡erentiation utilizing geneti-
cally lineaged C-33 and C-81 LNCaP cells since
they are derived from the same cell origin, and
may represent di¡erent stages of tumor progression
regarding androgen responsiveness [42], but not PC-3
cells. We utilized these two cells as our model system
for further studies.
3.2. E¡ect of steroid-depleted medium, IL-6, and
db-cAMP on PSA and AR expression in
LNCaP cells
To determine molecular changes that are associ-
ated with NE di¡erentiation of prostate cells, we
Fig. 3. Expression of NSE in human prostate cancer cells in
di¡erent growth conditions. Cells were maintained in a PR-pos-
itive medium supplemented with 5% FBS (C), a PR-negative
medium supplemented with 5% SR-FBS (SR), PR-negative me-
dium supplemented with 5% SR-FBS and 50 ng/ml IL-6 (IL-6),
or 5% SR-FBS and 1 mM db-cAMP (db-cAMP). Total cell ly-
sates were electrophoresed and transferred to nitrocellulose
membranes for Western blotting with anti-NSE antibody. A
portion of membrane was dissected for Coomassie blue staining
to show a similar amount of loaded protein in each lane (data
not shown). Similar results were obtained from three sets of in-
dependent experiments.
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analyzed the expression of PSA and AR in LNCaP
cells grown in di¡erent growth conditions. As shown
in Fig. 4A, in the SR medium in the presence or
absence of IL-6, the cellular level of PSA was down-
regulated in both C-33 and C-81 cells, although a
lesser e¡ect was obtained in C-33 cells. Db-cAMP
treatments resulted in an increase in the intracellular
level of PSA in both LNCaP cells (Fig. 4A). These
data were consistent with the secreted level of PSA in
Fig. 4. E¡ect of the steroid-depleted condition, IL-6, or db-cAMP on PSA and AR expression in LNCaP cells. C-33 and C-81 LNCaP
cells were plated and treated with 50 ng/ml IL-6 (IL-6) or 1 mM db-cAMP (db-cAMP) as described in Fig. 3. The same set of sam-
ples was used for Western blot analyses to detect the expression level of PSA (A) and AR (B). 30 Wg total lysate proteins and 25 Wl
medium were used for Western blot analyses on PSA level in LNCaP cell lysates and in their conditioned medium. The ratio of PSA
expression in cell lysates was similar to that in conditioned medium from LNCaP cells. Similar results were obtained from three sets
of independent experiments.
C
Fig. 5. Western blot analyses of RPTPK expression in LNCaP
cells. Cells were cultured at growth conditions in a PR-positive
medium supplemented with 5% FBS (C), PR-negative medium
supplemented with 5% SR-FBS (SR), PR-negative medium sup-
plemented with 5% SR-FBS and 50 ng/ml IL-6 (IL-6), or 5%
SR-FBS and 1 mM db-cAMP (db-cAMP). 30 Wg total lysate
proteins were electrophoresed and blotted on a nitrocellulose
membrane, and the membrane was subsequently hybridized
with anti-RPTPK antibody. It should be noted that a prolonged
exposure showed a low level of RPTPK expression in C-33 cells
grown in the IL-6-containing medium (data not shown). A por-
tion of membrane was dissected for Coomassie blue staining to
show a similar amount of loaded protein in each lane (data not
shown). Similar results were obtained from three sets of inde-
pendent experiments.
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the conditioned medium from those cells (Fig. 4A).
In the SR condition, the level of AR was elevated in
C-33 LNCaP cells, while markedly decreased in C-81
cells (Fig. 4B). IL-6 also caused an increase of AR in
C-33 cells, but a decrease in C-81 cells (Fig. 4B). Db-
cAMP exhibited a negative e¡ect on the AR level in
C-81 cells, but not in C-33 cells. Thus, PSA, an ep-
ithelial cell di¡erentiation marker, is regulated di¡er-
ently from NSE, a NE cell marker.
3.3. Expression of RPTPK in LNCaP cells during
neuroendocrine transdi¡erentiation
It has been shown that RPTPK plays a critical role
in neuronal di¡erentiation and signaling [60,62]. We
investigated if RPTPK may also be involved in pros-
tate NE di¡erentiation. As shown in Fig. 5, in cells
cultured in a SR medium, the level of RPTPK ex-
pression was increased in both LNCaP cells, corre-
lating with their morphological changes. However, in
cells grown in the presence of IL-6 or db-cAMP, the
expression of RPTPK was markedly decreased (Fig.
5). Thus, in the androgen-depleted condition, the ex-
pression of RPTPK correlates with phenotypic
changes of LNCaP cells, independent of their andro-
gen responsiveness. Furthermore, the expression of
RPTPK in these two cells has the same response in
di¡erent growth conditions.
Fig. 6. Transdi¡erentiation of LNCaP cells by sodium butyrate. (A) Morphology of NaBu-treated LNCaP cells. C-33 LNCaP cells
were treated for 3 days with NaBu (1.5 mM). Morphological changes were observed under phase contrast microscopy (100U). (B) Bu-
tyrate e¡ect on growth of C-33 and C-81 LNCaP cells. After seeding in 5% FBS for 3 days, cells in triplicate were fed with the fresh
medium containing 5% SR-FBS, and exposed to di¡erent concentrations of sodium butyrate as indicated in the ¢gure. Total cell num-
ber was counted at day 5. The bar represents the standard deviation from one set of experiments in triplicate. Similar results were ob-
tained from two sets of independent experiments. (C) Western blot analyses of NSE and RPTPK expression in NaBu-treated LNCaP
cells. Total protein lysates were electrophoresed and blotted to nitrocellulose membranes. The membrane was probed with anti-NSE
or anti-RPTPK antibody. Hybridization with anti-L-actin antibody was used as an internal control for equal loading of each lane.
Similar results were obtained from two sets of independent experiments.
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3.4. Sodium butyrate e¡ect on NSE and RPTPK
expression in LNCaP cells
To further examine the correlation of NSE and
RPTPK expression with NE di¡erentiation of pros-
tate carcinoma cells, sodium butyrate (NaBu) was
utilized to induce cell di¡erentiation [2,33]. NaBu
induced a NE-di¡erentiation phenotype (Fig. 6A),
similar to the IL-6 e¡ect (Fig. 1C) that correlated
with a diminished cell growth (Fig. 6B). Interestingly,
NaBu treatment resulted in an elevated level of NSE
and RPTPK protein in both LNCaP cells although it
had a lesser e¡ect with di¡erent dose^response pat-
terns in C-81 cells than in C-33 cells (Fig. 6C). Thus,
the treatment of LNCaP cells with NaBu leads to a
marked increase of NSE and RPTPK levels, which
correlates with a NE-like phenotype of LNCaP cells,
independent of androgen responsiveness of growth
regulation.
3.5. Trichostatin A e¡ect on NSE and RPTPK
expression in C-33 LNCaP cells
NaBu exhibits several biological e¡ects including
that it can function as an inhibitor of histone deace-
tylases (HDAC) and cause a hyperacetylation of core
histones. To investigate if histone hyperacetylation
has the same e¡ect on the expression of NSE and
RPTPK during NE di¡erentiation by NaBu, C-33
cells were treated with trichostatin A (TSA), a spe-
ci¢c HDAC inhibitor. As shown in Fig. 7, TSA in-
duced NSE expression in a dose-dependent manner,
while it inhibited the expression level of RPTPK. The
results thus indicated that the activation of RPTPK
expression by NaBu is mediated by the activation of
cellular pathways other than hyperacetylation of core
histones.
4. Discussion
Clinical results indicate that NE cells may play a
critical role in androgen-refractory growth of pros-
tate cancer cells [9]. While the origin of these NE
cells is not clearly de¢ned in clinical studies, recent
experimental studies have shown that prostate cancer
cells can directly give rise to cells with a NE-like
phenotype. This process is referred to as transdi¡er-
entiation [4,51,55]. Although di¡erent prostate can-
cer cells can be transdi¡erentiated into a similar NE
cell-like phenotype by di¡erent treatments [4,13,
26,51,55], there is no direct comparison among those
treatments in di¡erent cells. Thus, it is not clear if
di¡erent cells can follow the same pathway of trans-
di¡erentiation. The experimental work in this study
is to investigate molecular mechanisms of transdi¡er-
entiation in di¡erent prostate cancer cells including
di¡erent LNCaP cells. LNCaP cells are partially
di¡erentiated prostate cancer cells and express
PSA, a prostate epithelium-speci¢c di¡erentiation
marker. In di¡erent LNCaP cells, despite a similar
expression level of functional AR and PSA, the
responsiveness of androgen stimulation of cell prolif-
eration is altered, imitating prostate tumor progres-
sion [42]. Thus, di¡erent LNCaP cells represent an
interesting, unique cell model in studying the trans-
di¡erentiation of prostate cancer cells during tumor
progression.
In our experiments, the end product of prolonged
maintenance of C-33 LNCaP cells in the SR condi-
tion is a cell that resembles the phenotype of NE cells
much more than the morphology of prostate epithe-
lial cells. By growth in this condition, the altered
phenotype of NE transdi¡erentiated C-33 LNCaP
cells is dramatically di¡erent from that of control
cells with di¡erentiated characteristics of prostate ep-
ithelial cells (Fig. 1A vs. B). We found that andro-
Fig. 7. E¡ect of TSA on NSE and RPTPK expression in
LNCaP cells. C-33 LNCaP cells were plated at a density of
1U106 per T-75 £ask. 48 h after seeding, cells were treated for
48 h with di¡erent concentrations of TSA as indicated in the
¢gure. Total lysate proteins were separated on polyacrylamide
gels, transferred to nitrocellulose membrane, and probed with
an anti-NSE and anti-RPTPK antibody, respectively. Hybridiza-
tion with anti-L-actin antibody was used as a control for dem-
onstrating an equal loading of each lane. Similar results were
observed in two sets of independent experiments.
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gen-responsive C-33 LNCaP cells grown in steroid-
reduced condition express higher levels of di¡erent
markers of NE cells including NSE, NT, ChA and
GS than control cells (Figs. 2 and 3). Thus our re-
sults clearly showed that C-33 LNCaP cells can
undergo transdi¡erentiation into a cell type with
strong characteristics of NE cells, suggesting the pos-
sibility that such an event might underline the appar-
ent accumulation of NE cells in hormone-refractory
tumors. This phenomenon may also re£ect clinical
observations that, during androgen-ablation therapy,
the androgen-responsive prostate cancer cells can
transdi¡erentiate into NE-like cells, and the popula-
tion of NE cells is thus increased.
In archival specimens of normal, hyperplastic and
neoplastic human prostate, NE cells lack AR and are
considered to be androgen independent [8,36]. In
contrast to NE cells which are histologically consid-
ered nonproliferative [23] and represent a terminally
di¡erentiated cell population [6], we found that NE-
like cells derived from LNCaP cells still express AR
(Fig. 4B) and could proliferate in steroid-restricted
conditions. Furthermore, a recent report shows the
reversibility of the NE phenotype of LNCaP cells
[16], suggesting that the acquisition of NE character-
istics may be an epigenetic phenomenon that can
occur gradually, depending on the phenotypic poten-
tial of a cell and the in£uence of its environment.
These ¢ndings together indicate that there are appar-
ent di¡erences between NE-like cells and NE cells of
the prostate.
Interestingly, in C-81 cells grown in steroid-re-
duced condition, the NSE level was not increased,
while RPTPK had an increased expression as in C-
33 cells (Fig. 3 vs. Fig. 5). C-81 LNCaP cells are an
androgen-unresponsive subline of LNCaP cells and
express PSA (Fig. 4A and [42]). Thus, these cells
exhibit di¡erent biochemical properties from paren-
tal C-33 LNCaP cells. Although these cells express a
functional AR (Fig. 4B), their growth is androgen-
unresponsive [42] and exhibits a rapid growth rate in
steroid restricted condition, similar to androgen-in-
dependent PC-3 cells. In this condition, RPTPK ex-
pression, but not NSE, was increased in steroid-re-
stricted medium as parental C-33 cells. This could be
due to the fact that RPTPK is a di¡erent marker
from NSE, and involved in di¡erent cellular func-
tions in neuronal di¡erentiation. RPTPK may be in-
volved in the early stage of di¡erentiation, while
NSE is a di¡erentiated marker. The regulations of
their expressions are therefore via di¡erent molecular
mechanisms. The detailed molecular mechanism is
under investigation.
It has been reported that the IL-6 level in circula-
tion is elevated in a subset of patients with advanced
prostate carcinomas who have failed androgen-abla-
tion therapy [59]. Upregulation of IL-6 in these pa-
tients may be due to the negative regulation of the
IL-6 gene by androgenic hormones [5] since the ex-
pression of IL-6 receptor is increased after with-
drawal of androgens [43]. These ¢ndings together
point to the importance of cross-talks between IL-6
and androgen signaling pathways in prostatic carci-
nomas [45,50]. We have observed that IL-6-treated
LNCaP cells acquire a neuron-like morphology (Fig.
1C). To determine whether these IL-6-treated
LNCaP cells exhibit some characteristics of NE cells,
we analyzed the expression of NSE (Figs. 2 and 3).
We also compared these cells with poorly di¡erenti-
ated androgen-unresponsive PC-3 cells which express
a high basal level of NSE (Fig. 3). IL-6 has no e¡ect
on the NSE level in PC-3 cells, correlating with a
limited morphological change of these cells. How-
ever, IL-6 has an intriguing e¡ect in LNCaP cells.
In androgen responsive C-33 cells, although the
NSE level is higher in IL-6-treated cells than in con-
trol cells grown in the regular growth condition, the
NSE level is decreased, lower than in the SR alone.
On the contrary, in C-81 cells, the NSE level is high-
er in the IL-6-containing medium than in the SR
alone, indicating IL-6 counteracts the e¡ect by the
SR medium. The results clearly show that the intra-
cellular signaling of IL-6 is di¡erent in androgen-re-
sponsive and -unresponsive prostate cancer cells. One
possibility is that di¡erent signal transduction path-
ways are activated in those cells, due to di¡erences in
the expression of signaling molecules. For example, it
has been reported that PC-3 cells may not express
functional STAT3 [56], a transducer of IL-6 signal-
ing. Of course, there are other explanations. Further
studies are required to determine the IL-6 signaling
in prostate cancer cells.
It has been shown that cAMP can reverse the
transformed phenotype of some cancer cells, possibly
by restoring the normal regulatory pathway [3]. The
critical genes regulated by cAMP in prostate carci-
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noma cells may include genes that induce NE di¡er-
entiation as well as downregulate cell cycle progres-
sion. Our data show that an elevation of cAMP in-
duces transdi¡erentiation primarily in androgen-
unresponsive C-81 LNCaP and PC-3 cells, indicated
by NSE expression and morphology change.
Our data thus reveal that androgen-unresponsive
human prostate cancer cells respond di¡erently from
androgen-responsive cells to pharmacological treat-
ments. This phenomenon thus resembles the hetero-
geneity of prostate cancer cells. Furthermore,
although cAMP induces a dramatic change in the
phenotype of C-33 LNCaP cells (Fig. 1D), cAMP
caused a decrease of NSE in those cells (Figs. 2
and 3). The di¡erential responses of NSE expression
in di¡erent prostate cells is also similar to the re-
sponse of c-myc gene expression to protein kinase
C (PKC) action on those same cells [34]. Thus, a
similar change in gross phenotype may accompany
di¡erential gene expressions.
As described above, IL-6 and db-cAMP have dif-
ferential e¡ects on di¡erent prostate cancer cells. In
prostate cancer cells, results of several studies have
shown that IL-6 and db-cAMP can stimulate or in-
hibit cell growth, depending on the targeted cells. It
has been proposed that IL-6 and db-cAMP may
share the same MAPK signaling pathway through
a cross-talk with ErbB2 which activates the MAPK
pathway in LNCaP cells, while it inhibits it in PC-3
cells [11,50,56]. Taken together all these ¢ndings in-
dicate that PC-3 may respond di¡erently from
LNCaP cells in the presence of di¡erent pharmaco-
logical agents. The detailed molecular mechanisms
remain to be clari¢ed.
To further examine the regulatory mechanism of
transdi¡erentiation of human prostate cells, we uti-
lized di¡erent LNCaP cells, a genetically lineaged cell
model system. PSA is expressed only in di¡erentiated
secretory prostatic epithelial cells, and serves as a
marker of prostate di¡erentiation [14]. Both LNCaP
cells express a high level of PSA (Fig. 4A and [42]).
In our studies, IL-6 induces NE-like morphology
changes and has an inhibition of PSA expression in
both LNCaP cells. Contrarily, db-cAMP upregulates
the PSA level. It has been shown that human AR can
be activated through an alternate signaling pathway
involving db-cAMP in a ligand-independent manner
in prostate cancer cells [18,48]. The activation of AR
by db-cAMP can thus enhance the speci¢c activity of
AR, but not its protein level, which increases PSA
expression.
The transmembrane nature of the receptor-like
PTPs indicates that these PTPases can be involved
in transducing extracellular signals. RPTPK has a
high level of expression in brain [28,54], and can
associate with contactin, a neuronal cell adhesion
molecule, through the extracellular region [65]. Sev-
eral lines of evidence have demonstrated that RPTPK
plays a critical role in normal neuronal di¡erentia-
tion [20,60,67]. We have shown that in the steroid-
reduced condition, RPTPK expression in both
LNCaP cells is upregulated (Fig. 5), correlating
with the phenotype change (Fig. 1B). To understand
the possible functional role of RPTPK in prostate
NE transdi¡erentiation, NaBu is utilized since this
reagent can induce partial di¡erentiation of PC-3
cells [33]. This reagent is currently under clinical con-
sideration as a potential agent for the management
of advance prostate cancer [52]. However, the molec-
ular mechanism in this process is not completely
known. In this study, NSE and RPTPK are used as
markers to investigate the signaling pathway by
NaBu in cell di¡erentiation. Our data clearly show
that NaBu treatment results in morphological
changes and elevated NSE levels (Fig. 6), and thus
resembles a transdi¡erentiation pathway of LNCaP
cells. NaBu treatment results in an upregulation of
RPTPK expression in C-33 and C-81 LNCaP cells
(Fig. 6C). Since TSA is a speci¢c inhibitor of histone
deacetylases [63], it is a useful tool to study the role
of histone acetylation in the regulation of NSE and
RPTPK expression during NE di¡erentiation by bu-
tyrate. Unexpectedly, TSA induces a dose-dependent
activation of NSE, while it inhibits RPTPK expres-
sion in C-33 LNCaP cells (Fig. 7). Taken collectively
the data suggest that NaBu activation of NSE and
RPTPK expression is mediated by di¡erent signaling
pathways although both NaBu and TSA have a sim-
ilar e¡ect on histone acetylation. For the ¢rst time,
our data show that RPTPK may act as a molecular
mediator in the signaling pathway initiated by NaBu
although the link between sodium butyrate and
RPTPK remains to be identi¢ed. Since cell growth
and di¡erentiation can be regulated by protein phos-
phorylation and dephosphorylation, RPTPK may
play an important role in the modulation of gene
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expression for transdi¡erentiation of prostate carci-
noma cells during androgen-ablation therapy, and
may also serve as an additional marker for this pro-
cess.
Results of clinical studies show that the NE cell
population is increased in hormone-refractory carci-
nomas, although the origin of those NE cells is not
known. Based on our results, we propose that there
are multipathways for the transdi¡erentiation of
prostate cancer cells to NE-like cells. As shown in
Fig. 8, in normal prostate gland, NE cells are appar-
ently derived from prostate stem cells. Nevertheless,
hormonal-based prostate cancer therapies have the
potential of altering androgen-responsive prostate
cancer cells to NE-like cells in a manner that might
accelerate the development of more aggressive pros-
tate tumors. For androgen-unresponsive cells, an ad-
ditional pharmacological e¡ect is apparently required
to facilitate this transdi¡erentiation process. Taken
together, our data suggest that the transdi¡erentia-
tion process is responsible for the apparent accumu-
lation of NE cells in hormone-refractory tumors dur-
ing relapse progression.
In conclusion, the molecular process by which cul-
tured human prostate cancer cells undergo a trans-
di¡erentiation process to a NE cell-like phenotype is
accompanied by changes in the expression of di¡er-
ent protein markers. The NE cell-like phenotype can
occur by exposing prostate cancer cells to di¡erent
pharmacological agents. Furthermore, di¡erent mo-
lecular pathways can be involved in transdi¡erentia-
tion of di¡erent prostate cancer cells, indicating the
heterogeneity of prostate cancer. Thus, controlling
these signaling events may provide us with alterna-
tive therapeutic targets to block tumor progression.
Further studies are required to determine the func-
tional role of NE cells in the pathogenesis of prostate
carcinoma.
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